Synopsis
Synopsis
0
USDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine
2. Bactil
3. Busidril
4. Ebastel
5. Evastel
6. Kestin
7. Kestine
8. Las W-090
1. 90729-43-4
2. Kestine
3. Ebastel
4. Ebastin
5. Kestin
6. Bactil
7. Las W-090
8. Rp 64305
9. 4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one
10. Las-w-090
11. 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one
12. Las-w 090;rp64305
13. Rp-64305
14. Chembl305660
15. Tqd7q784p1
16. 4-(4-(benzhydryloxy)piperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one
17. Rp64305
18. Ncgc00164603-01
19. Evastel
20. Dsstox_cid_26472
21. Dsstox_rid_81644
22. Dsstox_gsid_46472
23. Ebastinum [latin]
24. Ebastina [spanish]
25. Ebastina
26. Ebastinum
27. Estivan
28. Bastel
29. Cas-90729-43-4
30. Unii-tqd7q784p1
31. Ebastine [usan:inn:ban]
32. 4-(4-(benzhydryloxy)piperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one
33. 4-[4-(benzhydryloxy)piperidin-1-yl]-1-(4-tert-butylphenyl)butan-1-one
34. 4-diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine
35. Las-w 090
36. No-sedat
37. Kestine (tn)
38. Mfcd00865661
39. 4'-tert-butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone
40. Ebastine [usan]
41. Ebastine [inn]
42. Ebastine [jan]
43. Ebastine [mi]
44. 4-(4-benzhydryloxy-1-piperidyl)-1-(4-tert-butylphenyl)butan-1-one
45. Ebastine [mart.]
46. Ebastine [who-dd]
47. 1-(4-(1,1-dimethylethyl)phenyl)-4-(4-(diphenylmethoxy)-1-piperidinyl)-1-butanone
48. Schembl18467
49. Ebastine [ep Impurity]
50. Ebastine (jp17/usan/inn)
51. Ebastine [ep Monograph]
52. Dtxsid6046472
53. Bdbm22873
54. Chebi:31528
55. Hms3261i03
56. Hms3887c19
57. Bcp08300
58. Hy-b0674
59. Zinc3781952
60. Tox21_112225
61. Tox21_500361
62. Bbl029069
63. Ebastine, >=98% (hplc), Solid
64. S4262
65. Stk624411
66. Akos005557491
67. Tox21_112225_1
68. Ccg-221665
69. Db11742
70. Ks-1349
71. Lp00361
72. Sdccgsbi-0633701.p001
73. 1-butanone, 1-(4-(1,1-dimethylethyl)phenyl)-4-(4-(diphenylmethoxy)-1-piperidinyl)-
74. Ncgc00164603-02
75. Ncgc00164603-04
76. Ncgc00164603-05
77. Ncgc00164603-11
78. Ncgc00261046-01
79. Ac-15213
80. Ac-30629
81. Be164400
82. Db-057220
83. E0925
84. Ft-0630975
85. W-090
86. A14946
87. C77079
88. D01478
89. Ab01325291-02
90. 729e434
91. A843625
92. Sr-01000883997
93. Q-201053
94. Q2327739
95. Sr-01000883997-1
96. 4-diphenylmethoxy-1[3-(4-tert-butylbenzoyl)propyl]-piperidine
97. Ebastine, United States Pharmacopeia (usp) Reference Standard
| Molecular Weight | 469.7 g/mol |
|---|---|
| Molecular Formula | C32H39NO2 |
| XLogP3 | 7.2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 10 |
| Exact Mass | 469.298079487 g/mol |
| Monoisotopic Mass | 469.298079487 g/mol |
| Topological Polar Surface Area | 29.5 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 594 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
R06AX22
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
R - Respiratory system
R06 - Antihistamines for systemic use
R06A - Antihistamines for systemic use
R06AX - Other antihistamines for systemic use
R06AX22 - Ebastine
Ebastine has known human metabolites that include 4-(4-tert-butylphenyl)-4-oxobutanal and Deslakylebastine.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
87
PharmaCompass offers a list of Ebastine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ebastine manufacturer or Ebastine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ebastine manufacturer or Ebastine supplier.
PharmaCompass also assists you with knowing the Ebastine API Price utilized in the formulation of products. Ebastine API Price is not always fixed or binding as the Ebastine Price is obtained through a variety of data sources. The Ebastine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ebastinum manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ebastinum, including repackagers and relabelers. The FDA regulates Ebastinum manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ebastinum API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ebastinum manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ebastinum supplier is an individual or a company that provides Ebastinum active pharmaceutical ingredient (API) or Ebastinum finished formulations upon request. The Ebastinum suppliers may include Ebastinum API manufacturers, exporters, distributors and traders.
click here to find a list of Ebastinum suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ebastinum Drug Master File in Japan (Ebastinum JDMF) empowers Ebastinum API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ebastinum JDMF during the approval evaluation for pharmaceutical products. At the time of Ebastinum JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ebastinum suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ebastinum Drug Master File in Korea (Ebastinum KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ebastinum. The MFDS reviews the Ebastinum KDMF as part of the drug registration process and uses the information provided in the Ebastinum KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ebastinum KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ebastinum API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ebastinum suppliers with KDMF on PharmaCompass.
A Ebastinum CEP of the European Pharmacopoeia monograph is often referred to as a Ebastinum Certificate of Suitability (COS). The purpose of a Ebastinum CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ebastinum EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ebastinum to their clients by showing that a Ebastinum CEP has been issued for it. The manufacturer submits a Ebastinum CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ebastinum CEP holder for the record. Additionally, the data presented in the Ebastinum CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ebastinum DMF.
A Ebastinum CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ebastinum CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ebastinum suppliers with CEP (COS) on PharmaCompass.
A Ebastinum written confirmation (Ebastinum WC) is an official document issued by a regulatory agency to a Ebastinum manufacturer, verifying that the manufacturing facility of a Ebastinum active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ebastinum APIs or Ebastinum finished pharmaceutical products to another nation, regulatory agencies frequently require a Ebastinum WC (written confirmation) as part of the regulatory process.
click here to find a list of Ebastinum suppliers with Written Confirmation (WC) on PharmaCompass.
Ebastinum Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ebastinum GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ebastinum GMP manufacturer or Ebastinum GMP API supplier for your needs.
A Ebastinum CoA (Certificate of Analysis) is a formal document that attests to Ebastinum's compliance with Ebastinum specifications and serves as a tool for batch-level quality control.
Ebastinum CoA mostly includes findings from lab analyses of a specific batch. For each Ebastinum CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ebastinum may be tested according to a variety of international standards, such as European Pharmacopoeia (Ebastinum EP), Ebastinum JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ebastinum USP).
